BAJAJ BROKING

Notification
No new Notification messages
Dhanlaxmi Crop Science IPO is Open!
Apply for the Dhanlaxmi Crop Science IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Suven Pharma Acquires 56% Stake in US-Based NJ Bio for ₹535 Crore

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Suven Pharma acquires a 56% stake in NJ Bio for ₹535 crore. The deal expands its addressable market from ₹1,600 crore to ₹11,600 crore.

Suven Pharma news today

Suven Pharmaceuticals Limited has acquired a 56% controlling stake in NJ Bio Inc, a US-based CRDMO specialising in antibody-drug conjugates (ADC) and emerging modalities. The ₹535 crore deal bolsters Suven’s position in the global ADC market, currently valued at $2.7 billion (approx ₹22,815 crore), with a projected annual growth rate exceeding 25%. This acquisition marks a strategic move to expand Suven’s addressable market from ₹1,600 crore to ₹11,600 crore.

Also read: Paytm Singapore to Sell SARs in PayPay for ₹2,364 Crore

SUVEN PHARMACEUTICALS LTD

Trade

1293.95-2.25 (-0.17 %)

Updated - 11 December 2024
1306.70day high
DAY HIGH
1287.05day low
DAY LOW
16216
VOLUME (BSE)

Key Takeaways

  • Investment Value: ₹535 crore for a 56% stake in NJ Bio.

  • Market Growth: ADC outsourcing market valued at ₹22,815 crore, growing at 25% annually.

  • Capacity Expansion: ₹124 crore allocated for NJ Bio’s Princeton facility expansion.

Also read: Welspun Corp Secures ₹1,300 Crore US Orders for Coated HSAW Pipes

Financial and Operational Highlights

NJ Bio, headquartered in Princeton, New Jersey, has served over 150 clients, completing more than 500 projects since inception. Its projected 2024 revenue stands at $32 million (approx ₹270 crore), reflecting a 70% CAGR since 2021. The deal includes ₹411 crore for acquiring shares from minority stakeholders and ₹124 crore in primary equity, earmarked for enhancing NJ Bio’s 80,000-square-foot facility.

Key Metrics

Value

Acquisition Cost

₹535 crore

NJ Bio’s 2024 Revenue

₹270 crore

ADC Market Size

₹22,815 crore

ADC Market Growth Rate

25% annually

Addressable Market Expansion

₹1,600 crore to ₹11,600 crore

Strategic Benefits

The acquisition aligns with Suven Pharma’s growth strategy, enhancing its capabilities in advanced drug modalities. The deal provides Suven access to NJ Bio’s expertise in ADCs, a high-growth segment, and positions it as a major player in the global CRDMO space.

Suven Pharma’s acquisition of NJ Bio marks a significant milestone in its expansion strategy. The ₹535 crore investment not only increases its global footprint but also significantly enhances its market potential. This move could positively influence the Suven Pharma share price, reflecting investor confidence in its growth trajectory.

Also read: Larsen & Toubro Triumphs in ₹702 Crore Tribunal Case, Customs Demand Quashed

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text